Agilent, Molecular Discovery join forces
Agilent Technologies Inc. announced that it has entered into a comarketing agreement with Molecular Discovery Ltd. to provide biopharmaceutical researchers with an advanced metabolite-identification platform. The companies will comarket the combined assets of Agilent's high-resolution liquid chromatography/mass spectrometry (LC/MS) technology and Molecular Discovery's Mass-MetaSite software to enable superior identification and analysis of complex biological mixtures.
This comarketing program provides customers with a turnkey solution that bridges the gap between sophisticated laboratory software and hardware capabilities. The analytical benefits of Agilent's high-resolution instruments, integrated with Molecular Discovery's robust predictive metabolite-identification software tools, will advance drug research and discovery by enabling the decisive identification and conversion of large volumes of data into usable information.Source: Agilent Technologies Inc.